JP2014510782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510782A5 JP2014510782A5 JP2014504431A JP2014504431A JP2014510782A5 JP 2014510782 A5 JP2014510782 A5 JP 2014510782A5 JP 2014504431 A JP2014504431 A JP 2014504431A JP 2014504431 A JP2014504431 A JP 2014504431A JP 2014510782 A5 JP2014510782 A5 JP 2014510782A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 4
- 102000034534 Cotransporters Human genes 0.000 claims 3
- 108020003264 Cotransporters Proteins 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- -1 cyano, carboxy Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161475493P | 2011-04-14 | 2011-04-14 | |
| US61/475,493 | 2011-04-14 | ||
| PCT/IB2012/051798 WO2012140596A1 (en) | 2011-04-14 | 2012-04-12 | Glycoside derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510782A JP2014510782A (ja) | 2014-05-01 |
| JP2014510782A5 true JP2014510782A5 (enExample) | 2015-06-11 |
Family
ID=46028034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504431A Pending JP2014510782A (ja) | 2011-04-14 | 2012-04-12 | グリコシド誘導体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8722633B2 (enExample) |
| EP (1) | EP2697240B1 (enExample) |
| JP (1) | JP2014510782A (enExample) |
| KR (1) | KR20140019834A (enExample) |
| CN (1) | CN103619862A (enExample) |
| AU (1) | AU2012241426A1 (enExample) |
| BR (1) | BR112013026361A2 (enExample) |
| CA (1) | CA2832951A1 (enExample) |
| EA (1) | EA201391524A1 (enExample) |
| MX (1) | MX2013011926A (enExample) |
| WO (1) | WO2012140596A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2719656T3 (es) | 2011-06-01 | 2019-07-11 | Green Cross Corp | Derivados de difenilmetano novedosos como inhibidores del SGLT2 |
| TR201908247T4 (tr) * | 2012-11-20 | 2019-06-21 | Lexicon Pharmaceuticals Inc | Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri. |
| US9394329B2 (en) | 2013-09-27 | 2016-07-19 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
| HUE053645T2 (hu) | 2013-11-18 | 2021-07-28 | Forma Therapeutics Inc | Tetrahidrokinolin kompozíciók mint BET bromodomén inhibitorok |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| SG11201810701XA (en) | 2016-06-02 | 2018-12-28 | Sanofi Sa | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein |
| EP4249479A4 (en) * | 2020-11-19 | 2024-12-18 | Beijing Increase Innovative Drug Co., Ltd. | GLUCOSIDE DERIVATIVE, ITS PREPARATION METHOD AND ITS APPLICATION |
| WO2022223480A1 (en) * | 2021-04-18 | 2022-10-27 | Ecole Polytechnique Federale De Lausanne (Epfl) | Green solvents for chemical reactions |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
| IL148384A0 (en) | 1999-08-31 | 2002-09-12 | Kissei Pharmaceutical | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| DE60115623T2 (de) | 2000-03-17 | 2006-07-06 | Kissei Pharmaceutical Co., Ltd., Matsumoto | Glucopyranosyloxy-benzylbenzen-derivate, medizinische zusammensetzung und zwischenprodukte für die herstellung der derivate |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| KR100647204B1 (ko) | 2000-09-29 | 2006-11-17 | 깃세이 야쿠힌 고교 가부시키가이샤 | 글루코피라노실옥시벤질벤젠 유도체 및 그것을 함유하는의약조성물 |
| US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| EP1432720A1 (en) | 2001-09-05 | 2004-06-30 | Bristol-Myers Squibb Company | O-pyrazole glucoside sglt2 inhibitors and method of use |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| ES2363941T3 (es) | 2003-03-14 | 2011-08-19 | Astellas Pharma Inc. | Derivados de c-glucósido para el tratamiento de diabetes. |
| AU2003902263A0 (en) | 2003-05-12 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Monosaccharide compounds |
| US7652061B2 (en) | 2003-05-20 | 2010-01-26 | Novartis A.G. | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors |
| ES2402098T5 (es) * | 2003-08-01 | 2021-06-09 | Mitsubishi Tanabe Pharma Corp | Compuestos novedosos que tienen actividad inhibidora frente a transportador dependiente de sodio |
| EP1680414A4 (en) | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | SUBSTITUTED INDAZOLE-O-GLUCOSIDE |
| EP1660509B1 (de) | 2003-08-26 | 2009-02-04 | Boehringer Ingelheim International GmbH | Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| NZ549219A (en) | 2004-03-04 | 2010-08-27 | Kissei Pharmaceutical | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| AU2005219779B2 (en) | 2004-03-04 | 2011-04-14 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| JP2008508213A (ja) | 2004-07-27 | 2008-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄ−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法 |
| WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| DE102004048388A1 (de) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| JP5086643B2 (ja) | 2004-11-18 | 2012-11-28 | キッセイ薬品工業株式会社 | １−置換−３−（β−Ｄ−グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬 |
| US20080027014A1 (en) | 2006-07-28 | 2008-01-31 | Tanabe Seiyaku Co., Ltd. | Novel SGLT inhibitors |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| KR101352934B1 (ko) * | 2009-06-19 | 2014-02-19 | 주식회사 녹십자 | 신규 ｃ―아릴 글루코사이드 ｓｇｌｔ２ 억제제 및 이를 포함하는 약학 조성물 |
| US8163704B2 (en) * | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
-
2012
- 2012-04-12 EP EP12719082.5A patent/EP2697240B1/en active Active
- 2012-04-12 KR KR1020137029814A patent/KR20140019834A/ko not_active Withdrawn
- 2012-04-12 JP JP2014504431A patent/JP2014510782A/ja active Pending
- 2012-04-12 BR BR112013026361A patent/BR112013026361A2/pt not_active IP Right Cessation
- 2012-04-12 EA EA201391524A patent/EA201391524A1/ru unknown
- 2012-04-12 US US13/634,597 patent/US8722633B2/en active Active
- 2012-04-12 AU AU2012241426A patent/AU2012241426A1/en not_active Abandoned
- 2012-04-12 CN CN201280028538.2A patent/CN103619862A/zh active Pending
- 2012-04-12 WO PCT/IB2012/051798 patent/WO2012140596A1/en not_active Ceased
- 2012-04-12 CA CA2832951A patent/CA2832951A1/en not_active Abandoned
- 2012-04-12 MX MX2013011926A patent/MX2013011926A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510782A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2011042668A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2009102342A5 (enExample) | ||
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2013500977A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| JP2014516942A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2013509411A5 (enExample) | ||
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| JP2019515908A5 (enExample) | ||
| JP2019529541A (ja) | 高サイトカイン血症及びウィルス感染の処置の為の肥満細胞安定剤 | |
| JP2015522033A5 (enExample) | ||
| JP2013518036A5 (enExample) | ||
| JP2012502915A5 (enExample) | ||
| US20240139224A1 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| JP2015522077A5 (enExample) | ||
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| JP2013541582A5 (enExample) | ||
| WO2014011949A3 (en) | Neuroprotective cb2 receptor agonists |